/ 2 items

#CLLS↓

Cellectis Scraps Allogeneic CAR-Ts and Bets on Heart Gene Editing

CLLS/ 09/15/2026 · 5:48 AM

Cellectis Drops Blood-Cancer CAR-Ts; Citizens Cuts Rating

Citizens cut Cellectis to Market Perform after it scrapped allogeneic CAR-T programs and pivoted to in-vivo gene editing for high triglycerides and cholesterol. Catalysts now 2027–28.

CLLS/ 06/09/2026 · 5:05 PM

Cellectis Receives FDA RMAT Status for lasme-cel – First Allogeneic CAR-T in Pivotal Trial for r/r B-ALL

Cellectis got FDA RMAT for lasme-cel, an off-the-shelf CAR-T therapy for hard-to-treat leukemia that may speed up patient access.